United States · 
What does Three Arch Partners invest in?
Three Arch Partners invests most often at Series B and Series C (50% of the rounds on record), in sectors such as Biotechnology and Dating.
Three Arch Partners highlights
- 01
75 rounds on record
- 02
Mostly Series B and Series C: 50% of its rounds
- 03
Sole investor in 2 rounds, median $11M
- 04
24 exits from the portfolio
What they do
- Type
- Growth equity (from a list, unverified)
- Cheque size
- Not stated
- Sectors
- BiotechnologyDating
- Based in
- United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first75 appearances
- 2015
1 round
- Apr
- 2013
2 rounds
- Nov
- Mar
- 2012
3 rounds
- Oct
- Jan
- Jan
- 2011
5 rounds
- Nov
- Jul
- May
- Mar
- Jan
- 2010
7 rounds
- Oct
- Jul
- Jun
- Jun
- Jun
- Apr
- Jan
- 2009
6 rounds
- Nov
- Oct
- May
- May
- May
- Feb
- 2008
13 rounds
- Oct
- Sept
- Sept
- Aug
- Aug
- May
- Apr
- Mar
- Mar
- Jan
- Jan
- Jan
- Jan
- 2007
11 rounds
- Oct
- Jul
- May
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 2 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed24 in all
LipoScienceBought by LabCorp$63MSept 2014
Access ClosureBought by Cardinal Health$320MApr 2014
SquareOneBought by Omnia MediaUndisclosedJan 2014
Tibion Bionic TechnologiesBought by AlterGUndisclosedJun 2013
Ingenuity SystemsBought by QiagenUndisclosedApr 2013
BaxanoBought by TranS1UndisclosedMar 2013
EpocratesBought by AthenahealthUndisclosedJan 2013
Calibra MedicalBought by Johnson & JohnsonUndisclosedJul 2012
Ascend HealthBought by Universal Health ServicesUndisclosedJun 2012
Cameron HealthBought by Boston ScientificUndisclosedJun 2012
HemosphereBought by CryoLife$22MMay 2012
VetCentricBought by Vets First ChoiceUndisclosedJan 2012
Calistoga PharmaceuticalsBought by Gilead Sciences$375MFeb 2011
EpocratesListedUndisclosedFeb 2011
ConcuityBought by The Advisory Board CompanyUndisclosedMar 2010
EvalveBought by Abbott Labs$410MSept 2009
VisiogenBought by Abbott Labs$400MSept 2009
Pegasus BiologicsBought by Synovis Life Technologies$12MJul 2009
Reliant TechnologiesBought by Thermage$66MJan 2009
LipoSonixBought by Medicis Pharmaceutical$300MJun 2008
The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.